Gout drugs use and risk of cancer: A case-control study - 15/11/18
pages | 7 |
Iconographies | 1 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Concerns have been raised regarding the risk of gout medications to cancer risk. |
• | Having lack of epidemiological evidence, this study shows the association between gout drugs and risk of cancer. |
• | Gout drugs are significantly increased risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer. |
Abstract |
Objective |
Firm conclusion about whether short and long-term gout medications use has an impact on cancer risk remain inconclusive. The aim of this study was to investigate the association between gout drugs use and risk of cancer.
Methods |
We conducted a retrospective longitudinal population-based case-control study in Taiwan. Cases were identified all patients who were aged 20years or above, and had a first time diagnosis of cancers for the period between 2001 and 2011. Adjusted odds ratios (AORs) and 95% confidence intervals (CIs) were calculated by using conditional logistic regression.
Results |
We examined 601,733 cases and 2,406,932 matched controls. The adjusted odd ratio for any gout drugs use and overall cancer risk was 1.007 (95% CI: 0.994–1.020). There was a significant risk of leukemia (AOR: 1.34, 95% CI: 1.20–1.50), endometrial cancer (AOR: 1.33, 95% CI: 1.12–1.57), non-Hodgkin's (AOR: 1.24, 95% CI: 1.13–1.35), female breast cancer (AOR: 1.21, 95% CI: 1.13–1.29), cervical cancer (AOR: 1.21, 95% CI: 1.07–1.37). However, no association was observed in male group (AOR: 0.97, 95% CI: 0.95–0.98) but female showed a significantly increased risk of cancer at any site (AOR: 1.107, 95% CI: 1.08–1.13).
Conclusion |
In summary, our results suggest that gout drugs increase risk of the most common cancers, particularly in leukemia, non-Hodgkin's, endometrial, breast and cervical cancer.
Le texte complet de cet article est disponible en PDF.Keywords : Gout drugs, Breast cancer, Cervical cancer, Allopurinol, Pharmacoepidemiology etc.
Plan
Vol 85 - N° 6
P. 747-753 - décembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?